Mark your calendar:
Join us to explore the future of cancer care at the ICPO Theranostics Virtual Summit, November 14-15, 2024
The ICPO Foundation is hosting a world-class scientific program featuring academic and industry experts focused on alpha emitters and new radiopharmaceuticals.
June 27, 2024 – Wiesbaden, Germany. Theranostics, a combination of diagnostics and therapy, is revolutionizing cancer treatment. By utilizing tailored radiopharmaceuticals, tumors can be precisely identified and treated, leading to high efficacy and minimal side effects. This personalized medicine approach is transforming oncology. The ICPO Theranostics Summit 2024, taking place on November 14-15, 2024, will feature a renowned scientific program delivered by over 30 distinguished experts from the ICPO Community. Our focus will be on exploring innovations, from basic research to clinical applications, initially in the field of alpha emitters, including actinium and more, and then across a range of new radiopharmaceuticals, such as FAP and beyond. Our goal is to collaboratively shape the contours of a new era in cancer care, ultimately benefiting patients globally.
Building upon the success of the inaugural ICPO Theranostics Summit in 2022, as well as the multiple FAP (Fibroblast Activation Protein) sessions hosted during the ICPO Forum in 2023 and the Theranostics World Congress earlier in 2024, the ICPO Foundation is delighted to announce its new ICPO Theranostics Summit 2024.
Whether attendees are well-versed in alpha emitters and new radiopharmaceuticals or are simply curious about their potential impact on clinical applications in their respective countries, the ICPO Theranostics Summit 2024 promises to be enlightening. In addition to insightful talks and dynamic panel discussions, there will also be an engaging Q&A session and a crucial debate on the present and future clinical significance of radiotheranostics in the context of improved patient outcomes and enhanced access to more personalized, comprehensive, and accessible cancer care.
Find the program and registration platform here:
About ICPO Foundation
The International Centers for Precision Oncology Foundation (ICPO) is a non-profit organization founded in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Recognizing a paradigm shift in cancer care from a one-size-fits-all approach to a personalized approach, the ICPO Foundation is actively building momentum to expand global patient access to Radiomolecular Precision Oncology to support this transformation. Consequently, the ICPO Foundation strives to develop an international network of physical diagnostic and therapeutic Centers for Precision Oncology, organized within a Social Franchise model built on shared expertise, certified education through the ICPO Academy for Theranostics, and design and process standardization that promotes best clinical practices worldwide. Furthermore, the ICPO Foundation aims to empower its Centers by integrating them into a highly inclusive Community that spearheads its model and fulfills the promise of Precision Oncology by making it accessible to all patients in need, regardless of their country or social status.
Learn more about the ICPO Foundation at and the ICPO Academy for Theranostics at
Media contact ICPO Foundation
Susanne Simon
Head of Communication & Community
Email:
Phone: + 49 172 8666093
Attachment